Search
Calidi Biotherapeutics Inc
CLDIAdd to Watchlist
1.090USD
-0.020-1.80%
Close 09-23 16:00（ET）
21.05MMarket Cap
LossP/E TTM
After-hours 19:48 (ET)1.230USD+0.150+13.89%
After-hours 19:48 (ET)CLDI Analyst Recommendation Trends
In the current month, CLDI has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CLDI average Analyst price target in the last month is 10.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
CLDI Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
Forecast
--
--
--
Actual
-0.57
-6.86
-47.01
Surprise
--
--
--
FAQs
What is the analyst rating for Calidi Biotherapeutics Inc?
Based on the ratings of Calidi Biotherapeutics Inc's stock from 0 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.